Relmada Therapeutics Inc
Company Profile
Business description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Contact
2222 Ponce de Leon Boulevard
Floor 3
Coral GablesFL33134
USAT: +1 786 629-1376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
stocks
Big four bank holds up in weakening economic conditions
stocks
Our view after Coles’ shares plunge
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,008.90 | 31.70 | 0.35% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,749.15 | 234.83 | -0.45% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,418.45 | 254.09 | 1.01% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,720.26 | 21.63 | 0.16% |
| S&P 500 | 7,577.76 | 36.36 | 0.48% |
| S&P/ASX 200 | 8,886.80 | 30.30 | 0.34% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |